Two significant entities of 2016 WHO classification based on IDH (Isocitrate dehydrogenase) gene mutant status are IDH wild-type and IDH mutated GBM; patients whose full IDH evaluation cannot be assessed are classified as GBM NOS (not otherwise specified) (Louis et al., 2016). This evidence concerns the gene IDH1 and glioblastoma.